SAVANNAH, Georgia — There’s no medical treatment for Charcot-Marie-Tooth (CMT) disease, a debilitating neurologic disorder that’s both progressive and incurable. But now, nerve specialists ...

and an estimated one million individuals with an inherited degenerative nerve condition called Charcot–Marie–Tooth disease type 2 (CMT2). Peripheral neuropathy can cause severe disability and ...

Mitochondria In Motion Inc. has identified new N-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide derivatives acting as mitofusin activators and reported to be useful for the treatment of Alzheimer’s, ...

The SynGAP Research Fund 501(c)(3) has awarded a pair of grants to Dr. Clement Chow, a geneticist and Associate Professor in the Department of Human Genetics at the University of Utah. These grants ...

Other laboratory tests to confirm the condition. Treatments can help manage condition, no known cure Diagnosed by medical professional Requires lab test or imaging A lifelong condition Certain ...

Avicenna received a patent covering ROCK inhibitor compounds for ALS, Parkinson’s, and other neurodegenerative conditions.

An east Auckland teenager with a rare genetic condition is grateful for having received equipment that will make it easier ...

In light of those characteristics, Cellatoz is applying NRPCs, in the form of CLZ-2002, to the treatment of Charcot–Marie–Tooth (CMT) type 1A disease and other health conditions caused by ...

Charcot-Marie-Tooth affects 1 in 2,500 people or approximately 2.6 million people worldwide. The disease causes progressive nerve damage and those with CMT ... Severe, chronic pain is common.

Thousands of people woke up to news that their bank is randomly closing down, and they must move their money ASAP.

The world’s defining voice in music and pop culture: breaking what’s new and what’s next since 1952.